A Phase II Study Of Epothilone B Analog BMS 247550 (NSC # 710428) In Stage IV Malignant Melanoma
I. Determine the efficacy of BMS-247550 in patients with stage IV melanoma. II. Determine
the toxicity of this drug in these patients.
OUTLINE: This is a multicenter study. Patients are stratified according to the number of
prior chemotherapy regimens (0 vs 1-2, including dacarbazine or temozolomide).
Patients receive BMS-247550 IV over 1 hour on days 1, 8, and 15. Courses repeat every 28
days in the absence of disease progression or unacceptable toxicity.
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
The 95% confidence intervals will be provided.
Up to 2 years
New York University Clinical Cancer Center
United States: Food and Drug Administration
|New York University Clinical Cancer Center||New York, New York 10016|